Drug Trial Radar · NCT06802224
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18,000
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Michigan; Henry Ford Health System; University of Washington; University of Texas Southwestern Medical Center; Wake Forest University Health Sciences; University of Virginia; University of Maryland; Duke University; University Health Network, Toronto
- First posted
- Jan 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Low blood pressure, also known as hypotension, is very common during major surgery under general anesthesia. Prolonged or severe hypotension can lead to complications such as kidney injury after surgery that slow down patient recovery. Anesthesiologists commonly administer medications called vasopressors to treat low blood pressure during surgery. These medications help raise the blood pressure back up to a safe range. Two vasopressor medications are commonly used for this purpose: norepinephrine and phenylephrine. Each of these medications has slightly different effects on the heart and blood vessels (cardiovascular system). It remains unknown which of these standard medications is better for treating low blood pressure during surgery. The goal of this clinical trial is to determine which of these two medications is better at preventing injury to the kidneys after major noncardiac surgery as well as other complications such as heart problems. Major surgeries are defined as those lasting at least two hours under general anesthesia. This trial will randomize about ten centers in North America to use either norepinephrine or phenylephrine as the primary medication to treat low blood pressure in adults undergoing major noncardiac surgery. Each hospital will prioritize one of the drugs each month, and the assigned drug will rotate each month at each hospital. No further participant involvement will be required as de-identified data are collected as part of standard medical care.
Conditions
- Anesthesia
- Surgery With General Anesthesia
- Noncardiac Surgery
- Hypotension During Surgery
- Acute Kidney Injury (AKI)
- Myocardial Injury After Noncardiac Surgery (MINS)
- Vasopressor
Interventions
NorepinephrineDrug
Intravenous Norepinephrine for both infusion and bolus dosing
PhenylephrineDrug
Intravenous Phenylephrine for both infusion and bolus dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute Kidney Injury (AKI)Time frame: 7 days
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California · Recruiting
University of Maryland
College Park, Maryland · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Wake Forest University School of Medicine
Winston-Salem, North Carolina · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
University of Washington
Seattle, Washington · Recruiting
University Health Network
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.